Research
Molecular
There is a surge of interest in unimolecular peptide hormone-based polypharmacy for obesity management.
Practitioners should stay informed about developments in peptide hormone therapies for obesity.
StrongSupportsmedium confidence
there has been a recent surge of interest in pursuit of both administration of individual peptide combinations as well as development of unimolecular peptide hormone-based polypharmacy.
Why this rating
The claim is based on emerging research trends.
Source
Is polypharmacy the future for pharmacological management of obesity?
Ryan A. Lafferty et al. · Current Opinion in Endocrine and Metabolic Research · 2022
reviewCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →